SNHG15 is reported to be significantly upregulated in a variety of cancer tissues compared with adjacent noncancer tissues [15–17], and abnormal overexpression of SNHG15 in cancer samples is associated with poor prognosis and high risk of metastasis in different cancers, including breast, colorectal, gastric, and prostate cancers [15, 18–28]. Here, SNHG15 is linked to prostate cancer.